Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

Autor:	Laviolette, Michel, Skjold, Tina, Nielsen, Læge Carl, Howarth, Peter, Russell, Richard J, Chachi, Latifa, FitzGerald, J Mark, Backer, Vibeke, Olivenstein, Ronald, Titlestad, Ingrid L, Ulrik, Charlotte Suppli, Harrison, Timothy, Singh, Dave, Chaudhuri, Rekha, Leaker, Brian, McGarvey, Lorcan, Siddiqui, Salman, Wang, Millie, Braddock, Martin, Nordenmark, Lars H, Cohen, David, Parikh, Himanshu, Colice, Gene, Brightling, Christopher E *
Zdroj:	In The Lancet Respiratory Medicine July 2018 6(7):499-510
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu